Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
The ten largest food and beverage companies in the world remain Nestle, Ahold Delhaize, PepsiCo., Archer Daniels Midland, Sysco, JBS, Performance Food Group, Anheuser-Busch InBev, Unilever, and Tyson Foods. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, GLP-1 drug demand shifts, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This May 2026 update revises our rankings using confirmed full-year 2025 results from company filings, SEC disclosures, and official press releases. Several rankings have shifted materially — most notably JBS, which reported record 2025 revenue of $86.2 billion and moves up from #6 to #4. Methodology: Rankings based on the most recent full fiscal year (FY2025) revenue from public filings, emphasizing ...
Artificial intelligence (AI) is redefining what wearable technology can do. In 2026, wearables are no longer passive tracking devices — they are becoming intelligent, predictive, and deeply personalized health and lifestyle companions. Source: Grand View Research Wearable technology market size was $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033, growing at a CAGR of 12.1% from 2026 to 2033. ( Grand View Research ) Recent advances in intelligent wearable systems: from multiscale biomechanical features towards human motion intent prediction (source: Nature 2026 ) A landmark study published in The Lancet (2026) , drawing on wearable data from more than 135,000 adults, found that even modest increases in daily movement — and small reductions in sedentary time — were associated with meaningfully lower mortality rates. Wearables are no longer just fitness tools; they are preventive medicine infrastructure. From smart rings and AI fitness coaches to augmen...
Wearable technology in 2026 is no longer just about counting steps or tracking calories. It has evolved into a continuous, AI-powered health intelligence system —capable of predicting disease, optimizing performance, and even augmenting human capabilities. A large study, published in The Lancet (2026) and drawing on wearable-device data from more than 135,000 adults, found that remarkably small increases in daily movement — and modest reductions in sitting — were associated with meaningful drops in mortality (death-rate). We are entering a new phase: Wearables → Health Intelligence Platforms Wearable technology market size was $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033, growing at a CAGR of 12.1% from 2026 to 2033. ( Grand View Research ) This article breaks down the most important innovations in wearable technology in 2026, and what they mean for consumers, healthcare, and investors. 1. Continuous Health Monitoring (24/7 Biometrics) Moder...
Table of Contents: Largest Pharma Companies by Revenue (Global Ranking) Top 10 Pharmaceutical Companies by Market Cap in 2025 Top 10 Most Anticipated Drug Launches of 2025 Top 10 Drugs Losing US Exclusivity in 2025 The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders. In 2025, the biggest pharmaceutical companies by revenue continued to dominate through scale, research spending, and global distribution—despite growing pressure from patent expirations, biosimilars, and pricing reforms. Medical stocks are releasing earnings reports in droves. Eli Lilly and Co (LLY.US) targets $80 billion in 2026 revenue with standout performance; Novo-Nordisk A/S (NVO.US) beats Q4 expectations but lowers 2026 guidance due to pricing pressures. The largest pharma companies are defined not only by revenue, but by global scale, research investment, and thera...
As of 2026, consumer wearables have evolved into powerful health intelligence tools—tracking everything from heart rate and sleep stages to recovery (HRV), blood oxygen (SpO2), stress, and even early illness signals. But here’s the reality: No wearable is a medical device. Even the best trackers provide trend-level insights—not diagnoses . This guide ranks the most accurate fitness trackers and wearables in 2026 , based on: Heart rate accuracy (especially during workouts) Step and distance tracking reliability Sleep tracking consistency Real-world battery life Depth of health and recovery insights We also factor in independent testing from sources like Wirecutter, Wareable, and CNET, plus real-world user feedback. Best Fitness Tracker Overall (2026): Garmin Venu 3 If you want one wearable that does almost everything well, this is it. Why it ranks #1: Among the most accurate wrist-based heart rate sensors Excellent GPS tracking (especially newer multi-band support) Industry-leading reco...
Artificial intelligence is no longer a theme—it is becoming the core infrastructure of global economic growth . From semiconductor design to cloud computing, automation, defense systems, and drug discovery, AI is now embedded across every major industry. The global generative AI market size is calculated at USD 25.8 billion in 2024 and is predicted to reach around USD 11.08 billion by 2034, expanding at a CAGR of 45.6% from 2024 to 2034. ( statifacts ) With hyperscalers (Microsoft, Amazon, Google, Meta) projected to spend over $500 billion on AI capex in 2026 alone (up from prior estimates), demand for data centers, chips, networking, cooling, and power is exploding. This isn't just hype—it's a multi-year buildout rivaling the internet era, with supply shortages persisting into 2026. Update: Best ETFs to Buy During the 2026 Energy Crisis (Protect Your Portfolio Now) Our "One-Day Decision" guide focuses on act...
Exchange-traded funds (ETFs) remain one of the best ways to build long-term wealth in 2026. With a single purchase, investors can gain diversified exposure to hundreds — or even thousands — of stocks, bonds, commodities, or thematic sectors. The biggest investing themes shaping 2026 include: Artificial intelligence (AI) infrastructure Semiconductor and data-center expansion Higher-for-longer interest rates Dividend and cash-flow investing Global diversification beyond mega-cap U.S. tech Nuclear energy and electrification Related: Top ETF Picks for April 2026 (War-Adjusted Portfolio Strategy) For most investors, the ideal ETF portfolio combines: Low costs Broad diversification Long-term compound growth Exposure to powerful secular trends like AI and automation Here are the best ETFs to consider in 2026. How These ETFs Were Selected Each ETF was evaluated based on: Long-term performance and liquidity Expense ratio and fund structure Relevance to current macro conditions Useful...
Last Updated: May 2026 | Reviewed by the One DayAdvisor Editorial Team Artificial intelligence is fundamentally changing what wearable technology can do. In 2026, wearables are no longer passive step counters — they are intelligent, predictive health and lifestyle companions that can detect illness early, coach your workouts, translate languages in real time, and monitor your brain activity while you sleep. The wearable technology market was valued at $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033 , growing at a CAGR of 12.1% ( Grand View Research ). That growth is being driven almost entirely by AI. This guide covers the 10 most important AI wearable innovations in 2026, with honest product picks, real-world tradeoffs, and the emerging trends shaping the next few years. Table of Contents AI-Driven Health Monitoring and Early Detection Generative AI Wellness Coaches Smart Rings as Powerful Health Platforms AI Smart Glasses and Augmented Reality Wearables ...
As we enter 2026, the memory and storage crunch predicted in late 2025 has materialized with even greater intensity. AI data centers continue to dominate global production of DRAM and NAND flash, pushing prices sharply higher and extending lead times across consumer, PC, and enterprise segments. Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM sta...
Reviewed by: OneDayAdvisor Editorial Team Last Updated: April 2026 The global oncology market is entering a new phase in 2026—defined by immunotherapy dominance, CAR-T expansion, and next-gen targeted therapies . While legacy giants still dominate revenue, earnings reports from Q1 2026 show a clear shift toward innovation-driven growth and aggressive M&A activity . This updated ranking incorporates: Latest Q1 2026 earnings data Oncology revenue trends Pipeline strength and strategic positioning Competitive threats (patent cliffs, biosimilars) Related: Latest Breakthroughs in Cancer Treatment In This Article: Merck (MRK) Bristol Myers Squibb Johnson & Johnson AstraZeneca Roche Novartis Eli Lilly (LLY) AbbVie Astellas Celgene 1. Merck & Co. Merck (MRK: NYSE ticker for Merck & Co. ) reported strong Q4 2025 results on Feb 3, 2026, with revenue of $16.4 billion (5% increase ...
Comments